Cargando…

Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study

BACKGROUND: Antiangiogenic therapy is a potential strategy against advanced refractory soft tissue sarcoma (STS). This retrospective study aimed to assess the efficacy and safety of apatinib in patients with advanced refractory STS and explore its clinical effect on the different histologic subtypes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiangling, Wang, Jian, Sun, Baoyong, Sun, Yuping, Liu, Ning, Niu, Xuecai, Li, Chunhua, Li, Li, Zhang, Qiang, Hao, Jing, Wang, Xiuwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577742/ https://www.ncbi.nlm.nih.gov/pubmed/36267758 http://dx.doi.org/10.21037/atm-22-3250

Ejemplares similares

Advanced alveolar soft part sarcoma responds to apatinib
por: Zhou, Yong, et al.
Publicado: (2017)

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial
por: Yu, Wenxi, et al.
Publicado: (2022)

Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China
por: Yang, Zhixun, et al.
Publicado: (2019)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study
por: Tian, Zhichao, et al.
Publicado: (2021)

Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
por: Long, Zuoyao, et al.
Publicado: (2021)

Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
por: Nakano, Kenji, et al.
Publicado: (2021)

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution
por: Wang, Yitian, et al.
Publicado: (2019)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study
por: Li, Ning, et al.
Publicado: (2020)

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
por: Tian, Zhichao, et al.
Publicado: (2019)

A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas
por: Zhou, Yan, et al.
Publicado: (2023)

The efficacy and safety of apatinib in Ewing’s sarcoma: a retrospective analysis in one institution
por: Wang, Yitian, et al.
Publicado: (2018)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China
por: Li, Feng, et al.
Publicado: (2017)

Pazopanib in rare histologies of metastatic soft tissue sarcoma
por: Kataria, Babita, et al.
Publicado: (2021)

Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study
por: Li, Ning, et al.
Publicado: (2021)

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019)

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

Radiographic and Histologic Response to Neoadjuvant Radiotherapy in Patients With Soft Tissue Sarcoma
por: Canter, Robert J., et al.
Publicado: (2010)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Apatinib in refractory radiation-induced brain edema: A case report
por: Hu, Wei Guo, et al.
Publicado: (2017)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
por: Lee, Ha-young, et al.
Publicado: (2012)

Integrative Clustering Reveals a Novel Subtype of Soft Tissue Sarcoma With Poor Prognosis
por: Zhu, Zhenhua, et al.
Publicado: (2020)

Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China
por: Peng, Wanren, et al.
Publicado: (2020)

Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
por: Zhang, Honghong, et al.
Publicado: (2017)

Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis
por: Tian, Zhichao, et al.
Publicado: (2020)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution [Corrigendum]
Publicado: (2019)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
por: Wang, Jiaqiang, et al.
Publicado: (2021)

Correction to: Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
Publicado: (2022)

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
por: Liu, Yanfei, et al.
Publicado: (2023)

Prognostic significance of histological invasion in high grade soft tissue sarcomas
por: Tsukushi, Satoshi, et al.
Publicado: (2014)

Accuracy of core needle biopsy for histologic diagnosis of soft tissue sarcoma
por: Kiefer, J., et al.
Publicado: (2022)

DNA methylation patterns–based subtype distinction and identification of soft tissue sarcoma prognosis
por: Li, Kai, et al.
Publicado: (2021)

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
por: Xie, Lu, et al.
Publicado: (2018)

Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer
por: Lin, Yansong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e8qphaliiqgt8tfeqcilfa4f75